TEL AVIV, Israel, March 25, 2020 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty,
clinical-stage pharmaceutical company focusing on the development
of cannabinoid-based treatments announced today that the Company
will host a conference call on Wednesday, April 22,
2020, at 4:30 PM EDT. ET
On the call, the Company will discuss the following topics:
- The Company's 2020 corporate vision and mission of the
company;
- The Company's plan to expand business through its subsidiaries;
and
- The Company's capital plan for 2020 and 2021.
The Dial in number will be +1 (978) 990-5000, access code
423748. There will also be a playback of the call starting at about
6:30 PM EDT on April 22, 2020. The playback number will be +1
(978) 990-5099, access code 423748. Those interested in submitting
questions prior and during the call can do so also by sending an
e-mail to IR@therapixbio.com.
About Therapix Biosciences (Nasdaq: TRPX):
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on
tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol
(CBD): THX-110 for the treatment of Tourette syndrome and for the
treatment of obstructive sleep apnea; THX-160 for the treatment of
pain; and THX-210 for the treatment of autism spectrum
disorder and epilepsy. Please visit our website for more
information at www.therapixbio.com, the content of which is
not a part of this press release.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, the Company is using forward-looking
statements when it discusses holding a shareholder conference call
and expanding business through its subsidiaries. Because such
statements deal with future events and are based on the Company's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
the Company could differ materially from those described in or
implied by the statements in this press release. The
forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" the Company's
Annual Report on Form 20-F filed with the SEC on May 15, 2019, the Company's registration
statement on Form F-1 filed with the SEC on March 19, 2020, and in subsequent filings with
the U.S. Securities and Exchange Commission. Except as otherwise
required by law, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/therapix-biosciences-ltd-announces-shareholder-conference-call-301029694.html
SOURCE Therapix Biosciences Ltd.